Lead Sponsor

Aristea Therapeutics, Inc.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•At least a 6-month history of PPP as defined by the presence of pustules on palms and/or soles, but without evidence of infection on palms and soles
•Moderate or severe PPP, as defined by Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) ≥8 and Palmoplantar Pustulosis Physician Global Assessment (PPPGA) ≥3 at Day -1, and a minimum of 8 fresh pustules at screening (fresh pustule count on both right/left palms and soles) and 20 fresh pustules at Day -1 (fresh pustule count on both right/left palms and soles)
•Males and females must be willing to use birth control as indicated

•Moderate to severe psoriasis, as defined by plaque psoriasis covering ≥10% of total Body Surface Area (BSA) at Day -1
•Subject is known to have an immune deficiency or is immunocompromised
•Positive test for hepatitis, human immunodeficiency virus (HIV) or tuberculosis
•Use of topical therapies for PPP within 2 weeks of Day -1 and/or systemic therapies for PPP within 4 weeks